Clarivate (NYSE:CLVT) Upgraded by Wall Street Zen to "Buy" Rating

Key Points

• Wall Street Zen upgraded Clarivate to a "Buy" rating from "Hold" in a recent research note, signaling at least one bullish analyst view.
• Despite that upgrade, the consensus is cautious: five analysts rate the stock Hold and three rate it Sell, with an overall average rating of "Reduce" and an average price target of $3.22 after multiple firms cut targets.
• Clarivate recently beat quarterly EPS estimates ($0.18 vs. $0.14) and reported $585.5M in revenue (down 1.4% YoY), set FY2026 guidance of 0.700–0.800 EPS, and its shares trade around $2.79 with a $1.78B market cap.

Clarivate (NYSE:CLVT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

A number of other research analysts have also weighed in on CLVT. Barclays reduced their price objective on shares of Clarivate from $4.00 to $2.40 and set an "underweight" rating for the company in a research note on Wednesday, February 25th. Royal Bank Of Canada reduced their price objective on shares of Clarivate from $5.00 to $3.00 and set a "sector perform" rating for the company in a research note on Wednesday, February 25th. Citigroup reduced their price objective on shares of Clarivate from $4.25 to $2.80 and set a "neutral" rating for the company in a research note on Wednesday, March 4th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Clarivate in a research note on Friday, March 27th. Finally, The Goldman Sachs Group lowered shares of Clarivate from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $4.20 to $3.60 in a research note on Thursday, January 8th. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $3.22.

Clarivate Trading Down 3.0%

NYSE:CLVT opened at $2.79 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $1.78 billion, a PE ratio of -13.26 and a beta of 1.41. The firm's 50 day moving average is $2.47 and its 200 day moving average is $2.95. Clarivate has a 12 month low of $1.66 and a 12 month high of $4.77.

Clarivate (NYSE:CLVT - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.04. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The company had revenue of $585.50 million for the quarter, compared to analysts' expectations of $569.50 million. During the same quarter in the previous year, the firm posted $0.14 EPS. Clarivate's revenue was down 1.4% on a year-over-year basis. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Sell-side analysts expect that Clarivate will post 0.63 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Personal CFO Solutions LLC bought a new position in Clarivate in the 1st quarter valued at $30,000. M&T Bank Corp bought a new position in Clarivate in the 4th quarter valued at $34,000. Essex Financial Services Inc. bought a new position in Clarivate in the 3rd quarter valued at $41,000. Jump Financial LLC bought a new position in Clarivate in the 4th quarter valued at $41,000. Finally, North Dakota State Investment Board bought a new position in Clarivate in the 4th quarter valued at $42,000. 85.72% of the stock is owned by institutional investors.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters' Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.